Stascheit Frauke, Aigner Annette, Mergenthaler Philipp, Hotter Benjamin, Hoffmann Sarah, Lehnerer Sophie, Meisel Christian, Meisel Andreas
Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Front Neurol. 2023 Jan 11;13:1056322. doi: 10.3389/fneur.2022.1056322. eCollection 2022.
This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG).
Sera from 134 patients with MG with varying degrees of disease severity and autoantibody (Abs) status were analyzed and compared to controls in a cross-sectional design. Prospectively, we additionally measured serum NfL (sNfl) levels in patients with MG longitudinally for up to 3 years. Based on linear regression, differences between patients and controls were assessed. With correlation coefficients and mixed linear regression, the association among sNfl levels, socio-demographics, disease activity (Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale), Abs-status (acetylcholine receptor antibody (AChR-Abs), muscle-specific receptor tyrosine kinase antibody (MuSK-Abs), lipoprotein-related protein 4 (LRP4), and seronegative), Abs titer, treatment regime (pyridostigmine, steroids, and immunosuppressive therapies), and thymectomy were investigated.
sNfl levels were higher in patients with MG compared to controls (median: 11.2 vs. 7.88), where sNfl levels were highest in anti-AChR-Abs positive patients (median 12.6), followed by anti-MuSK-Abs positive, anti-LRP4-Abs positive, and seronegative patients. Adjusting for age and sex, sNfl levels of patients with MG were on average 35% higher compared to controls (35.1, 95% CI: 8.4;68.3) and highest for patients with seronegative MG (44.35; 95% CI 16.47; 78.90). We found no relevant relationship between individual changes in sNfl and changes in QMG and MG-ADL scores.
sNfl levels are higher in patients with MG than in controls but were not consistently associated with clinical severity. Thus, sNfl is not a suitable biomarker to monitor individual disease progression in patients with MG.
本研究旨在评估重症肌无力(MG)患者血清中神经丝轻链(Nfl)与神经肌肉破坏及疾病严重程度之间的关联。
采用横断面设计,对134例疾病严重程度和自身抗体(Abs)状态各异的MG患者的血清进行分析,并与对照组进行比较。前瞻性地,我们还对MG患者的血清NfL(sNfl)水平进行了长达3年的纵向测量。基于线性回归,评估患者与对照组之间的差异。通过相关系数和混合线性回归,研究sNfl水平、社会人口统计学、疾病活动度(重症肌无力定量评分(QMG)和重症肌无力日常生活活动量表(MG-ADL))、Abs状态(乙酰胆碱受体抗体(AChR-Abs)、肌肉特异性受体酪氨酸激酶抗体(MuSK-Abs)、脂蛋白相关蛋白4(LRP4)和血清阴性)、Abs滴度、治疗方案(吡啶斯的明、类固醇和免疫抑制疗法)以及胸腺切除术之间的关联。
与对照组相比,MG患者的sNfl水平更高(中位数:11.2对7.88),其中抗AChR-Abs阳性患者的sNfl水平最高(中位数12.6),其次是抗MuSK-Abs阳性、抗LRP4-Abs阳性和血清阴性患者。调整年龄和性别后,MG患者的sNfl水平平均比对照组高35%(35.1,95%可信区间:8.4;68.3),血清阴性MG患者的sNfl水平最高(44.35;95%可信区间16.47;78.90)。我们发现sNfl的个体变化与QMG和MG-ADL评分的变化之间没有相关性。
MG患者的sNfl水平高于对照组,但与临床严重程度并非始终相关。因此,sNfl不是监测MG患者个体疾病进展的合适生物标志物。